CD4 and neoplasm: We previously demonstrated that RT39, but not its inactive point mutated form RT39M, exhibited a selective cytotoxicity toward Sézary patients’ primary tumor CD4+ cells ex vivo, while sparring non-malignant lymphocytes [16].